Evidence map›Paper›PMID 39887247›Full record

ArticleMicrobiology spectrum2025

Virus-host immune interaction in asymptomatic HTLV-1 carriers.

Theodore Worlanyo Asigbee, Midori Nakamura-Hoshi, Nozomi Kuse, Hiroshi Ishii, Koichi Ishikawa, Ai Kawana-Tachikawa, Erika Horibe, Makoto Nakashima, Yoshihisa Yamano, Kaoru Uchimaru and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Theodore Worlanyo Asigbee *Graduate School of Medical Sciences and Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Midori Nakamura-Hoshi *AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0002-4761-710X
Nozomi Kuse *Graduate School of Medical Sciences and Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.ORCID 0000-0003-3852-2288
Hiroshi IshiiAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0002-8126-1637
Koichi IshikawaAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Ai Kawana-TachikawaGraduate School of Medical Sciences and Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.ORCID 0000-0002-3082-5324
Erika HoribeDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
Makoto NakashimaDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
Yoshihisa YamanoDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
Kaoru UchimaruDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan.
Tetsuro MatanoGraduate School of Medical Sciences and Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.ORCID 0000-0003-3096-6749

Funding

Japan Agency for Medical Research and Development (AMED) JP22fk0108125, JP24fk0410059, JP24fk0108683, JP24bm1123025, JP24fk0108670, JP24wm0225039, JP243fa727002Ministry of Education, Culture, Sports, Science and Technology (MEXT) 22H04923Ministry of Education, Culture, Sports, Science and Technology (MEXT) 24K02291
6 · The paper itself

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) induces chronic long-term latent infection that can cause fatal diseases, including adult T-cell leukemia. HTLV-1 production is poor and undetectable during the asymptomatic phase of infection. Virus-host immune interaction in latent infection has not been fully determined. In the present study, virus-specific antibody and T-cell responses in asymptomatic HTLV-1 carriers ( IMPORTANCE: Human T-cell leukemia virus type 1 (HTLV-1) can cause fatal diseases, including adult T-cell leukemia in humans after long-term asymptomatic infection. In asymptomatic HTLV-1 carriers, substantial proviruses are detectable in lymphocytes, and the association of a higher proviral load with a higher risk of disease progression has been observed. However, viral replication is controlled and HTLV-1 production is poor in asymptomatic carriers. Virus-host immune interaction during latent infection has not been fully determined. In the present study, virus-specific antibody and T-cell responses in asymptomatic HTLV-1 carriers were investigated. Neutralizing antibody responses were positively correlated with proviral loads. Tax-specific CD8

Indexed as

Carrier StateHost Microbial InteractionsHTLV-I InfectionsHuman T-lymphotropic virus 1AdultAgedAntibodies, NeutralizingAntibodies, ViralAsymptomatic InfectionsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansInterferon-gammaMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralInterferon-gammaantibody responseHTLV-1neutralization activityT-cell immunity

Identifiers

PMID39887247
PMCPMC11878079

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.